FRI0636 The value of persistence in treatment with subcutaneous tnf-alpha inhibitors for ankylosing spondylitis Article Swipe
M Ivergård
,
Johan Dalén
,
Axel Svedbom
,
Christopher M. Black
,
Rebekah H. Borse
,
Sumesh Kachroo
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1136/annrheumdis-2018-eular.2100
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1136/annrheumdis-2018-eular.2100
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/annrheumdis-2018-eular.2100
- https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdf
- OA Status
- bronze
- Cited By
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2911015390
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2911015390Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/annrheumdis-2018-eular.2100Digital Object Identifier
- Title
-
FRI0636 The value of persistence in treatment with subcutaneous tnf-alpha inhibitors for ankylosing spondylitisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2018Year of publication
- Publication date
-
2018-06-01Full publication date if available
- Authors
-
M Ivergård, Johan Dalén, Axel Svedbom, Christopher M. Black, Rebekah H. Borse, Sumesh KachrooList of authors in order
- Landing page
-
https://doi.org/10.1136/annrheumdis-2018-eular.2100Publisher landing page
- PDF URL
-
https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdfDirect OA link when available
- Concepts
-
BASDAI, Medicine, BASFI, Ankylosing spondylitis, Persistence (discontinuity), Discontinuation, Etanercept, Physical therapy, Internal medicine, Demography, Arthritis, Tumor necrosis factor alpha, Psoriatic arthritis, Geotechnical engineering, Engineering, SociologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2911015390 |
|---|---|
| doi | https://doi.org/10.1136/annrheumdis-2018-eular.2100 |
| ids.doi | https://doi.org/10.1136/annrheumdis-2018-eular.2100 |
| ids.mag | 2911015390 |
| ids.openalex | https://openalex.org/W2911015390 |
| fwci | 0.0 |
| type | article |
| title | FRI0636 The value of persistence in treatment with subcutaneous tnf-alpha inhibitors for ankylosing spondylitis |
| biblio.issue | |
| biblio.volume | 77 |
| biblio.last_page | 841 |
| biblio.first_page | 840 |
| topics[0].id | https://openalex.org/T10804 |
| topics[0].field.id | https://openalex.org/fields/20 |
| topics[0].field.display_name | Economics, Econometrics and Finance |
| topics[0].score | 0.9962999820709229 |
| topics[0].domain.id | https://openalex.org/domains/2 |
| topics[0].domain.display_name | Social Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2002 |
| topics[0].subfield.display_name | Economics and Econometrics |
| topics[0].display_name | Health Systems, Economic Evaluations, Quality of Life |
| topics[1].id | https://openalex.org/T11092 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9922999739646912 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2745 |
| topics[1].subfield.display_name | Rheumatology |
| topics[1].display_name | Spondyloarthritis Studies and Treatments |
| topics[2].id | https://openalex.org/T10134 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.964900016784668 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1311 |
| topics[2].subfield.display_name | Genetics |
| topics[2].display_name | Inflammatory Bowel Disease |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777453003 |
| concepts[0].level | 4 |
| concepts[0].score | 0.7752163410186768 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q4834648 |
| concepts[0].display_name | BASDAI |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.767619252204895 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2780415856 |
| concepts[2].level | 5 |
| concepts[2].score | 0.683475136756897 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q4834653 |
| concepts[2].display_name | BASFI |
| concepts[3].id | https://openalex.org/C2777402515 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6288756132125854 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q52849 |
| concepts[3].display_name | Ankylosing spondylitis |
| concepts[4].id | https://openalex.org/C2781009140 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5297694206237793 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7170389 |
| concepts[4].display_name | Persistence (discontinuity) |
| concepts[5].id | https://openalex.org/C2778715236 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5022907257080078 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q55622662 |
| concepts[5].display_name | Discontinuation |
| concepts[6].id | https://openalex.org/C2777226972 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4892008304595947 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q415343 |
| concepts[6].display_name | Etanercept |
| concepts[7].id | https://openalex.org/C1862650 |
| concepts[7].level | 1 |
| concepts[7].score | 0.37361735105514526 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q186005 |
| concepts[7].display_name | Physical therapy |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3499886393547058 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C149923435 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3351617157459259 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q37732 |
| concepts[9].display_name | Demography |
| concepts[10].id | https://openalex.org/C2777077863 |
| concepts[10].level | 2 |
| concepts[10].score | 0.25109997391700745 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q170990 |
| concepts[10].display_name | Arthritis |
| concepts[11].id | https://openalex.org/C17991360 |
| concepts[11].level | 2 |
| concepts[11].score | 0.2268388569355011 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q21173843 |
| concepts[11].display_name | Tumor necrosis factor alpha |
| concepts[12].id | https://openalex.org/C2776260265 |
| concepts[12].level | 3 |
| concepts[12].score | 0.18257007002830505 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q511097 |
| concepts[12].display_name | Psoriatic arthritis |
| concepts[13].id | https://openalex.org/C187320778 |
| concepts[13].level | 1 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q1349130 |
| concepts[13].display_name | Geotechnical engineering |
| concepts[14].id | https://openalex.org/C127413603 |
| concepts[14].level | 0 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q11023 |
| concepts[14].display_name | Engineering |
| concepts[15].id | https://openalex.org/C144024400 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q21201 |
| concepts[15].display_name | Sociology |
| keywords[0].id | https://openalex.org/keywords/basdai |
| keywords[0].score | 0.7752163410186768 |
| keywords[0].display_name | BASDAI |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.767619252204895 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/basfi |
| keywords[2].score | 0.683475136756897 |
| keywords[2].display_name | BASFI |
| keywords[3].id | https://openalex.org/keywords/ankylosing-spondylitis |
| keywords[3].score | 0.6288756132125854 |
| keywords[3].display_name | Ankylosing spondylitis |
| keywords[4].id | https://openalex.org/keywords/persistence |
| keywords[4].score | 0.5297694206237793 |
| keywords[4].display_name | Persistence (discontinuity) |
| keywords[5].id | https://openalex.org/keywords/discontinuation |
| keywords[5].score | 0.5022907257080078 |
| keywords[5].display_name | Discontinuation |
| keywords[6].id | https://openalex.org/keywords/etanercept |
| keywords[6].score | 0.4892008304595947 |
| keywords[6].display_name | Etanercept |
| keywords[7].id | https://openalex.org/keywords/physical-therapy |
| keywords[7].score | 0.37361735105514526 |
| keywords[7].display_name | Physical therapy |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.3499886393547058 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/demography |
| keywords[9].score | 0.3351617157459259 |
| keywords[9].display_name | Demography |
| keywords[10].id | https://openalex.org/keywords/arthritis |
| keywords[10].score | 0.25109997391700745 |
| keywords[10].display_name | Arthritis |
| keywords[11].id | https://openalex.org/keywords/tumor-necrosis-factor-alpha |
| keywords[11].score | 0.2268388569355011 |
| keywords[11].display_name | Tumor necrosis factor alpha |
| keywords[12].id | https://openalex.org/keywords/psoriatic-arthritis |
| keywords[12].score | 0.18257007002830505 |
| keywords[12].display_name | Psoriatic arthritis |
| language | en |
| locations[0].id | doi:10.1136/annrheumdis-2018-eular.2100 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S25650217 |
| locations[0].source.issn | 0003-4967, 1468-2060 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0003-4967 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Annals of the Rheumatic Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310319945 |
| locations[0].source.host_organization_name | BMJ |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319945 |
| locations[0].source.host_organization_lineage_names | BMJ |
| locations[0].license | |
| locations[0].pdf_url | https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Annals of the Rheumatic Diseases |
| locations[0].landing_page_url | https://doi.org/10.1136/annrheumdis-2018-eular.2100 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5010797253 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | M Ivergård |
| authorships[0].affiliations[0].raw_affiliation_string | Mapi, Stockholm, Sweden |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | M. Ivergård |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Mapi, Stockholm, Sweden |
| authorships[1].author.id | https://openalex.org/A5060308735 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Johan Dalén |
| authorships[1].affiliations[0].raw_affiliation_string | Mapi, Stockholm, Sweden |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | J. Dalén |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Mapi, Stockholm, Sweden |
| authorships[2].author.id | https://openalex.org/A5015901006 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-2596-1679 |
| authorships[2].author.display_name | Axel Svedbom |
| authorships[2].affiliations[0].raw_affiliation_string | Mapi, Stockholm, Sweden |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | A. Svedbom |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Mapi, Stockholm, Sweden |
| authorships[3].author.id | https://openalex.org/A5001993231 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-2934-108X |
| authorships[3].author.display_name | Christopher M. Black |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[3].affiliations[0].raw_affiliation_string | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| authorships[3].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[3].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | C. M. Black |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| authorships[4].author.id | https://openalex.org/A5065890069 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Rebekah H. Borse |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[4].affiliations[0].raw_affiliation_string | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| authorships[4].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[4].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | R. H. Borse |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| authorships[5].author.id | https://openalex.org/A5068436236 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-7190-6323 |
| authorships[5].author.display_name | Sumesh Kachroo |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1285764155 |
| authorships[5].affiliations[0].raw_affiliation_string | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| authorships[5].institutions[0].id | https://openalex.org/I1285764155 |
| authorships[5].institutions[0].ror | https://ror.org/02891sr49 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I1285764155 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | S. Kachroo |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, United States |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | FRI0636 The value of persistence in treatment with subcutaneous tnf-alpha inhibitors for ankylosing spondylitis |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10804 |
| primary_topic.field.id | https://openalex.org/fields/20 |
| primary_topic.field.display_name | Economics, Econometrics and Finance |
| primary_topic.score | 0.9962999820709229 |
| primary_topic.domain.id | https://openalex.org/domains/2 |
| primary_topic.domain.display_name | Social Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2002 |
| primary_topic.subfield.display_name | Economics and Econometrics |
| primary_topic.display_name | Health Systems, Economic Evaluations, Quality of Life |
| related_works | https://openalex.org/W2052323610, https://openalex.org/W2418788079, https://openalex.org/W2034795592, https://openalex.org/W2254136192, https://openalex.org/W2157385191, https://openalex.org/W2184763072, https://openalex.org/W2124167119, https://openalex.org/W2529790253, https://openalex.org/W2765761756, https://openalex.org/W2113135028 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1136/annrheumdis-2018-eular.2100 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S25650217 |
| best_oa_location.source.issn | 0003-4967, 1468-2060 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0003-4967 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Annals of the Rheumatic Diseases |
| best_oa_location.source.host_organization | https://openalex.org/P4310319945 |
| best_oa_location.source.host_organization_name | BMJ |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319945 |
| best_oa_location.source.host_organization_lineage_names | BMJ |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Annals of the Rheumatic Diseases |
| best_oa_location.landing_page_url | https://doi.org/10.1136/annrheumdis-2018-eular.2100 |
| primary_location.id | doi:10.1136/annrheumdis-2018-eular.2100 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S25650217 |
| primary_location.source.issn | 0003-4967, 1468-2060 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0003-4967 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Annals of the Rheumatic Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310319945 |
| primary_location.source.host_organization_name | BMJ |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319945 |
| primary_location.source.host_organization_lineage_names | BMJ |
| primary_location.license | |
| primary_location.pdf_url | https://ard.bmj.com/content/annrheumdis/77/Suppl_2/840.2.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Annals of the Rheumatic Diseases |
| primary_location.landing_page_url | https://doi.org/10.1136/annrheumdis-2018-eular.2100 |
| publication_date | 2018-06-01 |
| publication_year | 2018 |
| referenced_works_count | 0 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/8 |
| sustainable_development_goals[0].score | 0.5199999809265137 |
| sustainable_development_goals[0].display_name | Decent work and economic growth |
| citation_normalized_percentile.value | 0.22037956 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |